Physician profile
Aja Errera
NPI 1689338931
$3,395.97
in general payments reported to CMS, 2019-2025
32 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.27 · 2022: $656 · 2023: $698 · 2024: $1,019 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.96 |
| Education | $203.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $635.52 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $258.51 | 2024-2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $247.44 | 2022-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $172.14 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $159.77 | 2022-2024 | Gardasil 9, Gardasil, Dificid |
| Amgen INC. | $157.35 | 2022-2025 | Evenity, Prolia |
| Pfizer INC. | $144.52 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $144.45 | 2023-2025 | Myfembree, Gemtesa |
| Acella Pharmaceuticals, LLC | $130.01 | 2023 | NP Thyroid 60 |
| Exeltis, USA INC. | $125.66 | 2023-2025 | Slynd |
| Organon LLC | $122.39 | 2022-2025 | Nexplanon |
| Abbvie INC. | $105.94 | 2022-2024 | |
| Myriad Women'S Health, INC. | $101.87 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $101.42 | 2024-2025 | Aptima |
| Novo Nordisk INC | $88.18 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $80.88 | 2025 | Ethicon, Stratafix |
| Mayne Pharma Commercial LLC | $70.07 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.63 | 2022 | |
| Lilly USA, LLC | $65.58 | 2022 | |
| Exact Sciences Corporation | $62.67 | 2024-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $61.25 | 2025 | Qelbree |
| Millicent US INC | $51.94 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $42.39 | 2023-2025 | Phexxi, Solosec, Phexx |
| Shield Therapeutics INC | $38.95 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.25 | 2022 | |
| Xeris Pharmaceuticals, INC. | $27.36 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $23.79 | 2022 | |
| Coopersurgical, INC. | $18.69 | 2024 | Paragard T 380a |
| Dynavax Technologies Corporation | $17.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.33 | 2022 | |
| Currax Pharmaceuticals LLC | $13.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aja Errera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.